Development of an Industrial Reference Sample for the Specific Activity of Erythropoietin


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

On the basis of WHO recommendations and the principles developed for the standardization of erythropoietins we selected one epoetin alfa pharmaceutical substances included in the State Register of Medicines as a candidate reference sample. The results of the manufacturer’s monitoring of this pharmaceutical substance complied with the requirements of the normative documentation and additional verification of identity by capillary zone electrophoresis demonstrated the presence of eight isoforms, which corresponded to the requirements of the European Pharmacopeia. Conditions for the preparation of an industrial reference sample in lyophilized form were developed. The industrial reference sample was attested in interlaboratory tests and the value of the attested property - specific activity - was 2400 IU/ampule, with confidence limits of 94.5% to 105.8%. Studies of the stability of the industrial reference sample developed here gave a shelf life of five years at a storage temperature of -20°C, with potential to extend this on the basis of stability monitoring results.

About the authors

A. K. Yakovlev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Author for correspondence.
Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

R. A. Volkova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

L. V. Simutenko

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

E. L. Postnova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

T. A. Batuashvili

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

A. A. Voropaev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

N. A. Alpatova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. A. Tomilin

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

E. D. Mytsa

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. P. Bondarev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. A. Merkulov

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Russian Federation, Building 2, 8 Petrovskii Boulevard, Moscow, 127051


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies